Chemotherapy and Targeted Therapy

Beyond Weight Loss: How Retatrutide is Redefining the Obesity Treatment Paradigm beyond-weight-loss-how-retatrutide-is-redefining-the-obesity-treatment-paradigm

Beyond Weight Loss: How Retatrutide is Redefining the Obesity Treatment Paradigm

Nana July 20, 2026

In the rapidly evolving landscape of metabolic medicine, Eli Lilly has signaled a major shift in how...

Shifting the Paradigm: How Ginkgo, Tangible, and Inductive Bio are Revolutionizing Early-Stage Drug Discovery shifting-the-paradigm-how-ginkgo-tangible-and-inductive-bio-are-revolutionizing-early-stage-drug-discovery

Shifting the Paradigm: How Ginkgo, Tangible, and Inductive Bio are Revolutionizing Early-Stage Drug Discovery

Ali Ikhwan July 19, 2026

In the high-stakes world of pharmaceutical research, the "fail fast, fail cheap" mantra has long been an...

Science and Scandal: ADA Conference Overshadowed by Political Protest and GLP-1 Breakthroughs science-and-scandal-ada-conference-overshadowed-by-political-protest-and-glp-1-breakthroughs

Science and Scandal: ADA Conference Overshadowed by Political Protest and GLP-1 Breakthroughs

Azzam Bilal Chamdy July 19, 2026

The American Diabetes Association’s (ADA) national conference, a cornerstone event for the global endocrinology community, concluded this...

The FDA’s Commissioner’s National Priority Voucher: A Paradigm Shift or Regulatory Chaos? the-fdas-commissioners-national-priority-voucher-a-paradigm-shift-or-regulatory-chaos

The FDA’s Commissioner’s National Priority Voucher: A Paradigm Shift or Regulatory Chaos?

Reynand Wu July 18, 2026

In June 2025, the U.S. Food and Drug Administration (FDA) unveiled the Commissioner’s National Priority Voucher (CNPV)...

GSK Abandons Camlipixant: A Major Setback in the Pursuit of a Chronic Cough Breakthrough gsk-abandons-camlipixant-a-major-setback-in-the-pursuit-of-a-chronic-cough-breakthrough

GSK Abandons Camlipixant: A Major Setback in the Pursuit of a Chronic Cough Breakthrough

Ammar Sabilarrohman July 18, 2026

By Jonathan Gardner Published July 17, 2026 In a significant blow to its respiratory pipeline, British pharmaceutical...

Merck’s Lipfendra Approval: A New Era for Cholesterol Management and a Litmus Test for FDA Reform mercks-lipfendra-approval-a-new-era-for-cholesterol-management-and-a-litmus-test-for-fda-reform

Merck’s Lipfendra Approval: A New Era for Cholesterol Management and a Litmus Test for FDA Reform

Nila Kartika Wati July 17, 2026

In a landmark decision that could reshape the landscape of cardiovascular health, the U.S. Food and Drug...

The God Molecule Gamble: Inside Eli Lilly’s $3.8 Billion Pivot to Psychedelic Medicine the-god-molecule-gamble-inside-eli-lillys-3-8-billion-pivot-to-psychedelic-medicine

The God Molecule Gamble: Inside Eli Lilly’s $3.8 Billion Pivot to Psychedelic Medicine

Dwi Wanna July 17, 2026

In a move that signals a seismic shift for the pharmaceutical industry, Eli Lilly has announced a...

The Psychedelic Frontier: Eli Lilly’s $3.8 Billion Bet on AtaiBeckley Signals a New Era for Big Pharma the-psychedelic-frontier-eli-lillys-3-8-billion-bet-on-ataibeckley-signals-a-new-era-for-big-pharma

The Psychedelic Frontier: Eli Lilly’s $3.8 Billion Bet on AtaiBeckley Signals a New Era for Big Pharma

Evan Lee Salim July 16, 2026

In a move that marks a tectonic shift in the pharmaceutical landscape, Eli Lilly has announced its...

The Psychedelic Paradox: Are We Overestimating the Efficacy of Psilocybin? the-psychedelic-paradox-are-we-overestimating-the-efficacy-of-psilocybin

The Psychedelic Paradox: Are We Overestimating the Efficacy of Psilocybin?

Nana Wu July 16, 2026

For years, the narrative surrounding classic psychedelics—particularly psilocybin—has been one of profound, almost miraculous transformation. In the...

Biopharma Mid-Year Pulse: J&J Earnings, Strategic M&A, and the Rise of AI-Driven Drug Discovery biopharma-mid-year-pulse-jj-earnings-strategic-ma-and-the-rise-of-ai-driven-drug-discovery

Biopharma Mid-Year Pulse: J&J Earnings, Strategic M&A, and the Rise of AI-Driven Drug Discovery

Muslim July 16, 2026

By Ben Fidler | Published July 15, 2026 The mid-point of 2026 has proven to be a...

Chemotherapy and Targeted Therapy

Beyond Weight Loss: How Retatrutide is Redefining the Obesity Treatment Paradigm

Shifting the Paradigm: How Ginkgo, Tangible, and Inductive Bio are Revolutionizing Early-Stage Drug Discovery

Science and Scandal: ADA Conference Overshadowed by Political Protest and GLP-1 Breakthroughs

The FDA’s Commissioner’s National Priority Voucher: A Paradigm Shift or Regulatory Chaos?

GSK Abandons Camlipixant: A Major Setback in the Pursuit of a Chronic Cough Breakthrough

Merck’s Lipfendra Approval: A New Era for Cholesterol Management and a Litmus Test for FDA Reform

The God Molecule Gamble: Inside Eli Lilly’s $3.8 Billion Pivot to Psychedelic Medicine

The Psychedelic Frontier: Eli Lilly’s $3.8 Billion Bet on AtaiBeckley Signals a New Era for Big Pharma

The Psychedelic Paradox: Are We Overestimating the Efficacy of Psilocybin?

Biopharma Mid-Year Pulse: J&J Earnings, Strategic M&A, and the Rise of AI-Driven Drug Discovery

You may have missed

Mastering the Gravity-Defying Flow: The Art of the Ashtanga Jump-Back

Cultivating Prosperity: The BRIDGES Engine and the Future of Rural Agriculture

A Lifesaving Breakthrough for BRCA Carriers: Cambridge Study Confirms Bilateral Salpingo-Oophorectomy Significantly Reduces Early Death Risk

The Pan-Viral Frontier: Can Cocrystal Pharma Rewrite the Rules of Antiviral Development?